Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18624759 | 0.92 | DHODH (0.85) | DHODHDHFR | |
| SCHEMBL18624760 | 0.92 | DHODH (0.85) | DHODHDHFR | |
| SCHEMBL18118634 | 0.89 | DHODH (0.80) | DHODHDHFR | |
| SCHEMBL26244623 | 0.88 | DHODH (0.78) | DHODHDHFR | |
| SCHEMBL517805 | 0.87 | DHODH (1.00) | DHODH | |
| SCHEMBL24180479 | 0.84 | DHODH (0.71) | DHODHDHFR | |
| Kio-100 SCHEMBL29869083 | 0.83 | DHODH (0.72) | DHODHDHFR | |
| SCHEMBL30693925 | 0.81 | DHODH (0.68) | DHODHDHFR | |
| SCHEMBL299933 | 0.79 | DHODH (1.00) | DHODHDHFR | |
| SCHEMBL26244615 | 0.78 | DHODH (0.64) | DHODHDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472263-B2 | Ophthalmic formulation | PANOPTES PHARMA GES.M.B.H (AT) | 2025-11-18 | — | — | US | claimed |
| US-12209073-B2 | Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor | KIORA PHARMACEUTICALS GMBH (AT) | 2025-01-28 | — | — | US | claimed |
| CN-119300819-A | Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor | 克奥拉制药股份有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-3761960-B1 | OPHTHALMIC FORMULATION | KIORA PHARMACEUTICALS GMBH (DE) | 2023-11-22 | — | — | EP | claimed |
| US-20230286938-A1 | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | PANOPTES PHARMA GMBH (AT) | 2023-09-14 | — | — | US | claimed |
| WO-2023172818-A1 | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | WO | claimed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | claimed |
| CN-111163757-B | Ophthalmic preparation | 帕诺泰斯制药有限公司 | 2022-04-19 | — | — | CN | claimed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | claimed |
| US-20210052737-A1 | OPHTHALMIC FORMULATION | PANOPTES PHARMA GES.M.B.H (AT) | 2021-02-25 | — | — | US | claimed |
| EP-3761960-A1 | OPHTHALMIC FORMULATION | Panoptes Pharma GmbH (AT) | 2021-01-13 | — | — | EP | claimed |
| CN-111163757-A | Ophthalmic preparation | 帕诺泰斯制药有限公司 | 2020-05-15 | — | — | CN | claimed |
| WO-2019170848-A1 | OPHTHALMIC FORMULATION | PANOPTES PHARMA GES.M.B.H. (AT) | 2019-09-12 | — | — | WO | claimed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | claimed |
| US-20170071904-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2017-03-16 | — | — | US | claimed |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | Panoptes Hparma GmbH (AT) | 2017-02-02 | — | — | US | claimed |
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| US-20250381167-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2025-12-18 | — | — | US | disclosed |
| WO-2004056797-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209073-B2 | Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor | DHODH, DPYD, DLD | DHODH 1/4885DHFR 8/4885 |
| US-20230286938-A1 | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | DHODH, DPYD, DLD | DHODH 1/4885DHFR 8/4885 |
| US-20170071904-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885 |
| US-20250381167-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885 |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, RPL35, NFKBIA | DHODH 2832/4885DHFR 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.